EPISODE · Jun 4, 2020 · 5 MIN
Novel approaches in multiple myeloma: TAK-079
from Multiple Myeloma Hub
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Amrita Krishnan, City of Hope, Duarte, US. In this podcast, she discussed the phase I data of TAK-079, a novel anti-CD38 monoclonal antibody, in a heavily pre-treated population of patients with multiple myeloma.She begins be describing the uniqueness of TAK-079 over other approved anti-CD38 antibodies and describes the mechanism of action. Amrita Krishnan then begins to discuss the promising safety and tolerability results including no infusion-related reactions and no significant lymphopenia or thrombocytopenia. Hosted on Acast. See acast.com/privacy for more information.
What this episode covers
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Amrita Krishnan, City of Hope, Duarte, US. In this podcast, she discussed the phase I data of TAK-079, a novel anti-CD38 monoclonal antibody, in a heavily pre-treated population of patients with multiple myeloma.She begins be describing the uniqueness of TAK-079 over other approved anti-CD38 antibodies and describes the mechanism of action. Amrita Krishnan then begins to discuss the promising safety and tolerability results including no infusion-related reactions and no significant lymphopenia or thrombocytopenia. Hosted on Acast. See acast.com/privacy for more information.
NOW PLAYING
Novel approaches in multiple myeloma: TAK-079
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.